Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $58.00 price target on the stock, up previously from $51.00.
LowReport
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $58.00 price target on the stock, up previously from $51.00.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock, up previously from $4.00.
HighReport
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock, up previously from $4.00.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: